News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

Board director in Egetis Therapeutics acquires shares

May 31, 2023

Stockholm, Sweden, May 31, 2023. Egetis Therapeutics AB (publ) (STO: EGTX) (the “Company”) today announced that Mats Blom, Board director, has acquired 200,000 additional shares in the Company on May 31, 2023. Mats Blom’s total holding in the Company now amounts to 3,134,762 shares.



Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10